The following amendment has been made to the Results of Annual General Meeting 2024 announcement released on 30th July 2024 at 16:00 under RNS No 4518Y.
To reappoint Alan Dunsmore as a Director: Against - No of votes 187,380; % of votes 0.08
All other details remain unchanged.
The full amended text is shown below.
SEVERFIELD PLC
Results of Annual General Meeting 2024
At the Company's Annual General Meeting held at 10 am today, 30 July, all of the resolutions were passed on a show of hands.
Copies of all the resolutions passed will be submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for review at Financial Conduct Authority website (https://data.fca.org.uk/#/nsm/nationalstoragemechanism).
A summary of Proxies received in respect of each resolution is set out below (a "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of the votes for and against the resolution):
| | | | | | | | |
| | In Favour | Against | Total | Withheld | | ||
| Resolution | No of votes | % of votes | No of votes | % of votes | No of votes | No of votes | |
| 1. To receive and adopt the annual accounts and the reports of the Directors for the financial year ended 30 March 2024 together with the report of the auditor thereon. | 224,715,655
| 99.99
| 15,333
| 0.01
| 224,730,988
| 1,544,070
| |
| 2. To approve the Directors' remuneration report (other than the part containing the Directors' remuneration policy) for the financial year ended 30 March 2024 as set out in the Annual Report and Accounts 2024. | 223,632,147
| 98.89
| 2,519,750
| 1.11
| 226,151,897
| 123,161
| |
| 3. To declare a final dividend of 2.3p per ordinary share in respect of the year ended 30 March 2024 payable on 11th October 2024 to shareholders on the register at the close of business on 6 September 2024. | 226,275,058
| 100.00
| 0
| 0
| 226,275,058
| 0
| |
| 4. To reappoint Alan Dunsmore as a Director. | 224,549,486
| 99.92
| 187,380
| 0.08
| 224,736,866
| 1,538,192
| |
| 5. To reappoint Derek Randall as a Director. | 226,039,563
| 99.91
| 208,183
| 0.09
| 226,247,746
| 27,312
| |
| 6. To reappoint Adam Semple as a Director. | 226,039,563
| 99.91
| 208,183
| 0.09
| 226,247,746
| 27,312
| |
| 7. To reappoint Louise Hardy as a Director | 201,396,641
| 95.80
| 8,826,734
| 4.20
| 210,223,375
| 16,051,683
|
|
| 8. To reappoint Mark Pegler as a Director | 217,319,212
| 96.07
| 8,895,490
| 3.93
| 226,214,702
| 60,356
|
|
| 9. To appoint Charlie Cornish as a Director | 216,313,296
| 97.54
| 5,445,549
| 2.46
| 221,758,845
| 4,516,213
|
|
| 10. To reappoint KPMG LLP as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company in 2025. | 224,521,568
| 99.28
| 1,634,873
| 0.72
| 226,156,441
| 118,617
|
|
| 11. To authorise the Audit Committee to determine the auditor's remuneration. | 226,192,534
| 99.99
| 32,681
| 0.01
| 226,225,215
| 49,843
|
|
| 12. To authorise the Directors to allot securities of the Company. | 225,961,374
| 99.87
| 285,458
| 0.13
| 226,246,832
| 28,226
| |
| 13. To authorise the Directors to dis-apply pre-emption rights in relation to the issue of securities of the Company. | 224,319,622
| 99.14
| 1,952,436
| 0.86
| 226,272,058
| 3,000
| |
| 14. To authorise the Directors to dis-apply pre-emption rights in connection with an acquisition or specified capital investment. | 224,300,635
| 99.13
| 1,971,423
| 0.87
| 226,272,058
| 3,000
| |
| 15. To authorise the Company to make market purchases of the Company's ordinary shares. | 224,594,144
| 99.29
| 1,611,329
| 0.71
| 226,205,473
| 69,585
| |
| 16. That a general meeting of the Company (other than an annual general meeting) may be called on not less than 14 clear days' notice. | 225,681,405
| 99.74
| 593,653
| 0.26
| 226,275,058
| 0
| |
| | | | | | | | |
Mark Sanderson
Company Secretary 31st July 2024
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
